CADTH Canadian Drug Expert Committee recommendation: Lixisenatide (Adlyxine -- Sanofi-Aventis Canada inc.) indication : diabetes mellitus, type 2
The CADTH Canadian Drug Expert Committee (CDEC) recommends that lixisenatide be reimbursed for use as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes mellitus
Corporate Authors: | , |
---|---|
Format: | eBook |
Language: | English |
Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
November 2017, 2017
|
Edition: | Version 1.0 |
Series: | CADTH common drug review
|
Subjects: | |
Online Access: | |
Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
Summary: | The CADTH Canadian Drug Expert Committee (CDEC) recommends that lixisenatide be reimbursed for use as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes mellitus |
---|---|
Item Description: | "Final." |
Physical Description: | 1 PDF file (9 pages) |